The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | What is the role of targeting the NOD2 mutation outside of PD-1 therapy?
Megan Babette Barnet, MD, The Kinghorn Cancer Centre, Darlinghurst, Australia, explains what the role of NOD2 mutation outside of PD-1 therapy, which is difficult to study in patients, as germline sequencing is not routine in patients with non-small cell lung cancer, and the number of patients not exposed to PD-1 is minimal. Studies using mice are trying to uncover a baseline effect of NOD2 deficit. Furthermore, the abscopal clinical case is being emulated in mice via bilateral flank tumor formation through inoculation, with one tumor irradiated and observation of the contralateral tumor for abscopal response. PD-1 treatment has been shown to influence the microbiome, however this research is still its infancy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
